LSAG
RPRX icon

Lake Street Advisors Group’s Royalty Pharma RPRX Stock Holding History

Lake Street Advisors Group’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,462
Closed -$211K – 671
2024
Q3 		$211K Buy
+7,462
New +$207K 0.01% 546
2024
Q2 		– Sell
-7,464
Closed -$227K – 655
2024
Q1 		$227K Buy
7,464
+197
+3% +$5.81K 0.01% 533
2023
Q4 		$204K Buy
+7,267
New +$200K 0.01% 541

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lake Street Advisors Group's RPRX Position: Q4 2024 in Review

Lake Street Advisors Group sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 7,462 shares — an estimated $211K sold.

Lake Street Advisors Group first reported a position in RPRX in Q4 2023 and held it in 3 quarters. The position peaked at $227K in Q1 2024. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Lake Street Advisors Group reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Lake Street Advisors Group sold 7,462 Royalty Pharma shares in Q4 2024, an estimated $211K.
  • Lake Street Advisors Group first reported a position in Royalty Pharma in Q4 2023 and held it in 3 quarters.
  • Lake Street Advisors Group's Royalty Pharma position peaked at $227K in Q1 2024.
  • 416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Lake Street Advisors Group's 13F filing for Q4 2024, filed 4 Feb 2025.